Skip to main content
INVION LIMITED logo

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2011-12-27 Director's Dealing
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Final Director`s Interest Notice x 2 4 pages 17.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the securities interests of directors who have ceased to be directors, including options and performance rights held. The content is focused on personal share transactions and interests of company directors. There is no financial performance data, earnings information, or report publication details. The document is a formal notification of directors' personal share transactions and interests, which aligns with the definition of Director's Dealing filings.
2011-12-27 English
Response to ASX query 6 pages 87.2KB
Regulatory Filings Classification · 95% confidence The document is a detailed correspondence between CBio Limited and ASX Limited regarding compliance with ASX Listing Rules, specifically Listing Rule 3.1 and 3.1A, about the timing and disclosure of material information related to Novo Nordisk's decision not to exercise an option agreement. The document includes questions from ASX and detailed responses from the company explaining the timing and rationale for disclosure. It is not a financial report, earnings release, or management discussion. It is a regulatory compliance communication addressing disclosure obligations and confidentiality under listing rules. The document is lengthy (over 12,000 characters) and contains substantive content, but it is not a report or announcement of financial results or corporate governance changes. It fits best as a Regulatory Filing (RNS) because it is a regulatory compliance correspondence and does not fit other categories such as Earnings Release, Annual Report, or Board/Management Information.
2011-12-20 English
Clarification to Response letter 1 page 23.1KB
Regulatory Filings Classification · 95% confidence The document is a short clarification letter addressing an error in a previously released market response letter. It discusses share price and trading volume details for specific dates but does not contain any financial statements, detailed financial data, or comprehensive report content. The length is only 1189 characters, indicating it is a brief announcement rather than a full report. It is addressed to the ASX Company Announcements Office, typical for regulatory or market disclosures. There is no indication that this is a full financial report, earnings release, or management discussion. It is also not a voting result, director dealing, or capital change notice. The content fits best as a Regulatory Filing (RNS) because it is a market clarification and does not fit other specific categories.
2011-12-20 English
Amended Change of Director`s Interest Notice 2 pages 80.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and details changes in securities holdings by a company director, including the number of shares disposed and held after the change. It references ASX listing rules and the Corporations Act, indicating it is a regulatory disclosure related to insider trading or director share transactions. The content is specific to a director's personal share transactions and does not contain financial results, management discussion, or other report types. Therefore, it fits the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3292 characters, consistent with a typical director dealing notice. Hence, the correct classification is DIRS with high confidence.
2011-12-20 English
Change of Director`s Interest Notice 3 pages 81.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in a director's relevant interests in securities, including the number of shares disposed and held before and after the change. It also discusses whether the trade occurred during a closed period and if prior clearance was obtained. This type of document is a report of personal share transactions by company directors and executives, commonly known as a director's dealing notice. It is not a financial report, regulatory filing, or announcement of a report but a specific disclosure of insider trading activity by a director.
2011-12-20 English
Change of Director`s Interest Notice 2 pages 79.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in shareholding, including the number of securities disposed and held after the change. The document is a formal notification of a director's personal share transactions. It does not contain financial statements or company performance data, nor is it a report or announcement of a meeting or vote. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3466 characters, consistent with a short notice rather than a full report. Therefore, the correct classification is DIRS.
2011-12-18 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.